卓正医疗1月29日至2月3日招股 预计2月6日上市

Group 1: Company Overview - The company, 卓正医疗, is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market targeting affluent individuals with a disposable income exceeding RMB 200,000 per year [2] - Established in 2012, the company operates 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [3] - The company aims to expand its network through organic growth and strategic acquisitions, particularly in new first-tier cities [3] Group 2: Market Position and Growth - In 2024, private mid-to-high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in China's mid-to-high-end medical service market, representing about 5.6% of the overall healthcare market [2] - The total revenue of China's private mid-to-high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion in 2024, with a compound annual growth rate (CAGR) of 21.9% [2] - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2] Group 3: IPO Details - The company plans to offer 4.75 million shares globally, with 10% allocated for Hong Kong and 90% for international sales, and an additional 15% over-allotment option [1] - The expected price range for the shares is HKD 57.7 to 66.6, with trading anticipated to commence on February 6, 2026 [1] - The estimated net proceeds from the global offering are approximately HKD 219 million, which will be allocated for various strategic initiatives, including AI application development and upgrading existing medical facilities [4]